Instrument Inactif

Communiqués Agile Therapeutics, Inc.

Actions

AGRX

US00847L3087

Recherche biotechnologique et médicale

Communiqués

29/08/24	Agile Therapeutics : IMPORTANT REMINDER TO HOLDERS OF WARRANTS OF AGILE THERAPEUTICS	PU
26/08/24	Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.	AQ
12/08/24	Agile Therapeutics: Q2 Earnings Snapshot	AQ
29/06/24	AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX	BU
26/06/24	Agile Therapeutics Inc. Announces Definitive Merger Agreement with Insud Pharma, S.L.	AQ
15/05/24	AGILE THERAPEUTICS : REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Form 8-K	PU
15/05/24	Agile Therapeutics: Q1 Earnings Snapshot	AQ
15/05/24	Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	AQ
28/03/24	Agile Therapeutics: Q4 Earnings Snapshot	AQ
28/03/24	Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update	AQ
25/03/24	Agile Therapeutics Announces Delisting from Nasdaq	AQ
21/03/24	Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024	AQ
20/03/24	Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024	AQ
13/03/24	Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution	AQ
22/02/24	Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds	AQ
15/02/24	Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update	AQ
24/01/24	AGILE THERAPEUTICS - THE BIDEN-HARRIS ADMINISTRATION ANNOUNCES NEW GUIDANCE TO ENABLE EXPANDED ACCESS TO ALL FDA-APPROVED CONTRACEPTIVES WITHOUT COST	AQ
23/01/24	The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost	AQ
12/12/23	Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement	AQ
09/11/23	Agile Therapeutics: Q3 Earnings Snapshot	AQ
09/11/23	Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	AQ
26/10/23	Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023	AQ
05/10/23	AGILE THERAPEUTICS REPORTS AN INDUCEMENT GRANT TO NEW CHIEF FINANCIAL OFFICER UNDER NASDAQ LISTING RULE 5635(4)	AQ
04/10/23	Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/09/23	Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	AQ